Grifols falls on report Brookfield delays offer on funding issues
Grifols (NASDAQ:GRFS) dropped 3% after a report that Brookfield (BAM) is delaying a takeover bid due to issues raising money ...
Brookfield still pursuing Grifols deal, Bloomberg reports
EST Brookfield still pursuing Grifols (GRFS) deal, Bloomberg reports Published first on TheFly – the ultimate source for ...
The Corner1d
SEC concludes investigation into Grifols over Gotham City report, no penalties announced
The Securities and Exchange Commission (American stock market regulator) reportedly concluded its investigation into Grifols ...
New Atlas10d
World-first treatment to prevent long-term eye damage from mustard gas
Global healthcare company Grifols has partnered with BARDA, the Biomedical Advanced Research and Development Authority, to ...
pharmaphorum7d
Could Spain’s Grifols be heading for de-listing?
The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...
Grifols (NASDAQ:GRFS) Raised to Strong-Buy at Berenberg Bank
Berenberg Bank upgraded shares of Grifols (NASDAQ:GRFS – Free Report) to a strong-buy rating in a report released on Tuesday, Zacks.com reports. Grifols Price Performance Shares of NASDAQ GRFS opened ...
Yahoo Finance7d
Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value
Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion. Operations ...
Morningstar3d
Grifols SA ADR GRFS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
1 man dead, 1 in custody after plasma center shooting, witnesses say shooter warned them
Police were called to the scene about 3 p.m. A man was pronounced dead and another was in custody, officials said.
Yahoo Finance15d
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it ...